Using MUNE to make linear estimates of rate of progression in ALS

Supplements to Clinical Neurophysiology

Volumn 55, Issue C, 2003, Pages 177-183

  Armon, Carmel ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957083447     PISSN: 1567424X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-424X(02)55019-4     Document Type: Review

References (18)

1. Andres P.L., Finison L.J., Conlon T., Thibodeau L.M., and Munsat T.L. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 38 (1988) 405-408
2. Armon C. Motor neuron disease. In: Gorelick P.B., and Alter M. (Eds). Handbook of Neuroepidemiology (1994), Marcel Dekker, New York 407-456
3. Armon C., and Brandstater M.E. Motor unit number estimates and quantitative muscle strength: a validation study. Muscle Nerve 20 (1997) 1072-1073
4. Armon C., and Brandstater M.E. Motor unit number estimate-based rates of disease progression of ALS predict patient survival. Muscle Nerve 22 (1999) 1571-1575
5. Armon C., and Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J. Neurol. Sci. 160 Suppl. 1 (1998) S37-S41
6. Armon C., Brandstater M.E., and Peterson G.W. Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis. Muscle Nerve 20 (1997) 499-501
7. Armon C., Graves M.C., Moses D.E., Forte D.K., Sepulveda L., Darby S.M., and Smith R.A. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23 (2000) 874-882
8. Bradley W.G. for the BDNF Phase III Study Group. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology, 1999 Apr 22, 52(7): 1427-1433.
9. Bromberg M.B. Electrodiagnostic studies in clinical trials for motor neuron disease. J. Clin. Neurophysiol. 15 2 (1998) 117-128
10. Brooks B.R., Sufit R.L., DePaul R., Tan Y.D., Sanjak M., and Robbins J.A. Design of clinical therapeutic trials in amyotrophic lateral sclerosis. In: Rowland L.P. (Ed). Advances in Neurology 56, (1991), Raven Press, New York 521-546
11. Bryan W.W., Barohn R., Murphy J.R., Armon C., Miller R.G., Goodpasture J., Parry G.J., Petajan J., Ross M.A., Stromatt S., and the ALS/SSNJV Study Group. Placebo versus natural history in an ALS clinical trial. Neurology 45 Suppl. 4 (1995) A280-A281
12. Consensus Guidelines for the Design and Implementation of Clinical Trials in ALS Appendix 5, Statistical Considerations. Second Airlie House Workshop, 1998. http://www.wfnals.org.
13. Daube J.R. Estimating the number of motor units in a muscle. J. Clin. Neurophysiol. 12 (1995) 585-594
14. McComas A.J. Invited review: motor unit estimation: methods, results, and present status. Muscle Nerve 14 (1991) 585-597
15. McComas A.J., Fawcett P.R.W., Campbell M.J., and Sica R.E.P. Electrophysiological estimation of the number of motor units within a human muscle. J. Neurol. Neurosurg. Psychiatry 34 (1971) 121-131
16. Miller R.G., Petajan J., Bryan W.W., Armon C., Barohn R.J., Goodpature J.C., Hoagland R.J., Parry G.J., Ross M.A., Stromatt S., and the rhCNTF ALS Study Group. A placebo-controlled trial of recombinant human Ciliary Neurotrophic Factor (rhCNTF) in amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 256-260
17. Munsat T.L., Hollander D., Andres P., and Finison L. Clinical trials in ALS: measurement and natural history. In: Rowland L.P. (Ed). Advances in Neurology 56 (1991), Raven Press, New York 515-519
18. *SPSS Base 7.5 for Windows. User's Guide. SPSS Inc., Staff. C. 1996. Pap. text ed. 41.00 (0-13-657214-6) P-H.